Overview

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To demonstrate that the effectiveness of brexpiprazole (2-4 mg/day) on quality of life is non-inferior to that of risperidone (4-6 mg/day) in adult patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
H. Lundbeck A/S
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Brexpiprazole
Risperidone